A single-center, prospective, observational study on the effectiveness and safety of omalizumab in Chinese patients with moderate-to-severe allergic asthma in real-world clinical settings

Study identification

• EU PAS number:
  EUPAS49571
• Study ID:
  49572
• Official title and acronym:
  A single-center, prospective, observational study on the effectiveness and safety of omalizumab in Chinese patients with moderate-to-severe allergic asthma in real-world clinical settings
• DARWIN EU® study:
  No
• Study countries:
  China
• Study status:
  Finalised

Research institutions and networks

Institutions

Beijing Chao-Yang Hospital, Capital Medical University

Department of Respiratory and Critical Care Medicine

Study timelines

Date when funding contract was signed

Planned:19/09/2017

Actual:19/01/2018

Study start date

Planned:19/12/2017

Actual:19/03/2018

Date of final study report

Planned:01/09/2022

Actual:14/10/2022

Sources of funding

Other

More details on funding

Beijing Natural Science Foundation of China

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable